ARID1A and neoplasm: Somatic AT-rich interaction domain 1A (ARID1A) mutations are present in up to 55% of OCCC tumours, and concomitant activation of the phosphoinositide 3-kinase (PI3K) catalytic subunit promotes tumour growth [7,8].